Retatrutide
Our Retatrutide Metabolic Optimization Program utilizes a cutting-edge triple receptor agonist to achieve profound weight loss and superior glycemic control. This once-weekly injectable therapy works by targeting GLP-1, GIP, and glucagon receptors, offering a multi-faceted approach to improve metabolic health. Patients can expect substantial reductions in body weight, enhanced blood sugar regulation, and benefits across various metabolic conditions like liver steatosis and diabetic kidney disease.
Quick answer
Pioneering Retatrutide therapy offers significant weight loss and comprehensive metabolic health improvements for obesity and Type 2 Diabetes.
Options
Pick what fits
Benefits
What to expect
- Significant Body Weight Reduction
- Improved Glycemic Control (HbA1c Reduction)
- Reduction in Liver Steatosis
- Relief of Knee Osteoarthritis Pain in Obese Patients
Ideal for
Who this helps
Adults with Obesity (BMI >30 kg/m²)Adults with Type 2 Diabetes Mellitus seeking improved glycemic control and weight managementIndividuals with metabolic syndrome components seeking comprehensive metabolic improvement
How it works
The procedure
01
Retatrutide acts as a triple receptor agonist, activating GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and glucagon receptors.
02
Activation of GLP-1 and GIP receptors enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite.
03
Glucagon receptor agonism may increase energy expenditure and fat metabolism, contributing to significant weight loss.
04
The combined effect leads to profound reductions in body weight, improved glycemic control, and beneficial metabolic adaptations across multiple organ systems.
Conditions
Treats
FAQ
Frequently asked
More services






